Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.80 |
| ▸ | PLK1 | P53350 | 12/20 | 0.80 |
| ▸ | INSR | P06213 | 4/20 | 0.64 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10310045 | 0.88 | KDR (0.78) | KDRPLK1INSRPTK2AURKB | |
| SCHEMBL1183638 | 0.88 | KDR (0.87) | KDRPLK1INSRPTK2AURKB | |
| SCHEMBL1184976 | 0.85 | PLK1 (0.74) | KDRPLK1INSRPTK2AURKB | |
| SCHEMBL1185186 | 0.85 | KDR (0.74) | KDRPLK1INSRPTK2AURKB | |
| SCHEMBL10309999 | 0.85 | KDR (1.00) | KDRPLK1INSRPTK2AURKB | |
| SCHEMBL1184654 | 0.85 | KDR (0.78) | KDRPLK1INSRPTK2AURKB | |
| SCHEMBL1184818 | 0.84 | KDR (0.72) | KDRPLK1INSRPTK2AURKB | |
| SCHEMBL1184168 | 0.82 | KDR (0.70) | KDRPLK1INSRPTK2AURKB | |
| SCHEMBL10310402 | 0.82 | KDR (0.74) | KDRPLK1INSRPTK2AURKB | |
| SCHEMBL1185193 | 0.82 | KDR (0.69) | KDRPLK1INSRPTK2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935694-B2 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | PRKCI, PIK3CA, AKT1 | KDR 3047/4885PLK1 69/4885INSR 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.